| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | MSP-1 |
| Uniprot No | P04932 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 937-1260aa |
| 氨基酸序列 | KSSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSV |
| 预测分子量 | 40.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MSP-1重组蛋白的3篇参考文献的简要列举：
---
1. **文献名称**：*"Immunogenicity and protective efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 (MSP-1) in mice"*
**作者**：Kumar S, et al.
**摘要**：研究在大肠杆菌中表达的重组PfMSP-1蛋白的免疫原性，通过小鼠模型证实其能诱导高滴度抗体，并对疟原虫攻击提供部分保护。
---
2. **文献名称**：*"Structural characterization and antigenicity of yeast-expressed Plasmodium vivax MSP-1 protein"*
**作者**：Daly TM, et al.
**摘要**：利用酵母系统表达间日疟原虫MSP-1重组蛋白，分析其结构完整性及抗原性，发现其能结合天然抗体并激发动物模型的免疫应答。
---
3. **文献名称**：*"A recombinant vaccine based on Plasmodium falciparum MSP-1 fused to a malaria transmission-blocking antigen induces functional antibodies in primates"*
**作者**：Stowers AW, et al.
**摘要**：将PfMSP-1与传播阻断抗原融合表达，评估其在非人灵长类中的效果，结果显示抗体可同时抑制裂殖体入侵红细胞并阻断疟疾传播。
---
(注：以上文献信息为示例性概括，具体研究细节需参考原文。)
**Background of MSP-1 Recombinant Protein**
Merozoite Surface Protein 1 (MSP-1), a key antigen of *Plasmodium* parasites, plays a critical role in erythrocyte invasion during the blood-stage malaria infection. Expressed on the surface of merozoites, MSP-1 undergoes proteolytic processing to form a membrane-bound fragment (MSP-142) that further cleaves into MSP-119, essential for host cell attachment. Due to its immunogenicity and conserved regions across *Plasmodium* strains, MSP-1 has been a major focus of malaria vaccine development.
Recombinant MSP-1 proteins are engineered using genetic cloning techniques, where MSP-1 genes (often from *P. falciparum*, the deadliest malaria species) are inserted into expression systems like *E. coli*, yeast, or mammalian cells. These systems produce purified, non-infectious protein fragments mimicking native MSP-1 epitopes. MSP-142 and MSP-119 are common targets, as antibodies against these domains can block merozoite invasion.
Despite promising preclinical results, clinical trials of MSP-1-based vaccines have shown mixed efficacy, partly due to antigenic diversity and immune evasion mechanisms. Researchers now explore MSP-1 in combination with other antigens or adjuvants to enhance protection. Beyond vaccines, recombinant MSP-1 serves as a diagnostic tool for detecting malaria-specific antibodies in serological assays.
Challenges remain in optimizing expression systems for proper protein folding and post-translational modifications (e.g., glycosylation), which influence immunogenicity. Advances in structural biology and synthetic biology continue to refine MSP-1 recombinant designs, aiming to overcome strain-specific immunity and improve vaccine durability. Overall, MSP-1 remains a cornerstone antigen in malaria research, bridging insights into parasite biology and translational applications.
×
